Phosphorylation of Protein Kinase C-alpha on Serine 657 Controls the Accumulation of Active Enzyme and Contributes to Its Phosphatase-resistant State*

(Received for publication, October 22, 1996, and in revised form, November 19, 1996)

Frédéric Bornancin Dagger and Peter J. Parker §

From the Imperial Cancer Research Fund, Lincoln's Inn Fields, London WC2A 3PX, United Kingdom

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

Serine 657 in protein kinase C-alpha (PKCalpha ) is a site of phosphorylation on expression of the recombinant protein in mammalian cells. To define the function of this phosphorylation, PKCalpha species with mutations of this site were investigated. The alanine mutant, S657A PKCalpha , displayed slow phosphate accumulation in pulse-chase experiments, indicating a rate-limiting role in the initial phase of phosphorylation. Consistent with this, the aspartic acid mutant, S657D PKCalpha , showed an increased rate of phosphate accumulation. Both the S657D and S657A PKCalpha mutants were slow to accumulate as fully phosphorylated forms during a second phase of phosphorylation. This latter property is shown to correlate with an increased phosphatase sensitivity and decreased protein kinase activity for these two PKCalpha mutants. It is further shown that once fully phosphorylated, the S657D PKCalpha mutant displays WT PKCalpha properties with respect to thermal stability and phosphatase sensitivity in vitro and in vivo; in contrast, the S657A PKCalpha mutant remains sensitive. The properties of the Ser-657 site PKCalpha mutants define functional roles for this phosphorylation in both the accumulation of phosphate on PKCalpha as well as in its agonist-induced dephosphorylation. These results are discussed in the context of a working model of PKCalpha behavior, providing insight into the workings of other kinases with equivalent sites of phosphorylation.


INTRODUCTION

The phosphorylation of protein kinases has long been established in the field of protein phosphorylation. In fact, the first target of regulated phosphorylation to be elucidated (phosphorylase b) lies at the end of a protein kinase cascade, wherein the cAMP-dependent protein kinase phosphorylates and activates phosphorylase kinase (see Ref. 1). Such cascades are now relatively commonplace among the protein kinase class, and there are many examples of positive regulatory cascades (e.g. the Raf-MEK-MAPK cascade) (2) and some of negative regulatory ones (e.g. PKB-GSK-3) (3). In these contexts, the effects of phosphorylation are reflected by a "simple" loss or gain of protein kinase activity. In a number of well characterized cases, the gain of function is associated with phosphorylation within what has been termed the "activation loop" of the kinase domain (see Ref. 4).

Contrary to the kinases referred to above, the cAMP-dependent protein kinase is regulated acutely through the cellular production of the second messenger cAMP (see Ref. 5, and references therein), and there is no evidence of acute regulation through modified phosphorylation within the activation loop. Nevertheless, it is evident that this region in its phosphorylated state plays a key role in aligning the substrate binding site for catalysis (6, 7). Members of the related protein kinase C (PKC)1 family are also second messenger-dependent protein kinases. For PKCalpha and PKCbeta , homologous sites in their activation loops have been shown to play an essential role (8-11). Thus, while these second messenger-dependent protein kinases may not be the subject of acute regulation through these phosphorylation sites, a similar requirement for phosphorylation pertains.

Although the activation loop phosphorylation sites in PKC and other protein kinases share a defined, necessary role in catalysis, phosphorylation of PKC sites outside this region plays a more subtle role in controlling function. In both PKCalpha and PKCbeta , phosphorylation of two C-terminal sites has been reported (11, 12). In PKCalpha , one of these, threonine 638 (Thr-638), has been shown to control the rate of agonist-induced dephosphorylation and inactivation of the protein in vivo but not to be required for catalytic activity (13). This property appears to be governed by interactions between the C-terminal region of the kinase and its catalytic core, with phosphorylation at Thr-638 and at the activation loop (Thr-497) being required to maintain the active, phosphatase-resistant, closed conformation of the kinase domain (13). Here, we have analyzed the role of the serine 657 (Ser-657) phosphorylation site in PKCalpha . It is established that phosphorylation of this site controls the accumulation of phosphate at other sites on PKCalpha , as well as contributing to the maintenance of the phosphatase-resistant conformation.


EXPERIMENTAL PROCEDURES

Mutagenesis

Bovine protein kinase C-alpha (14) was tagged with six histidine residues at the N terminus (His-tag PKCalpha ) by synthesizing oligonucleotide cassettes for substitution insertion. It was mutagenized and sequenced using the Altered Sites in vitro mutagenesis system (Promega) and the Sequenase Version 2.0 DNA sequencing kit (U. S. Biochemical Corp.) and finally subcloned into the pKS1 vector according to a previously described procedure (13). The following mutagenic oligonucleotides, which are sense with respect to the PKCalpha cDNA, were used (changed bases are underlined; an additional point mutation was designed, introducing a snab 1 restriction site with no change at the protein level): S657A, CTGATTTTGAAGGCTTC<UNL>G</UNL>CCTACGT<UNL>A</UNL>AACCCCCAGTTCG; S657D, CTGATTTTGAAGGCTTC<UNL>GA</UNL>CTACGT<UNL>A</UNL>AACCCCCAGTTCG; S657E, CTGATTTTGAAGGCTTC<UNL>GAA</UNL>TACGT<UNL>A</UNL>AACCCCCAGTTCG. The mutations at the 497 and 638 sites were prepared as described previously (13).

Transfection and Treatments of COS-1 Cells

COS-1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) fetal-calf serum, 1000 units/ml penicillin, and 100 µg/ml streptomycin. 50 µg of plasmid DNA were introduced into 0.8 ml of 60-80% confluent COS-1 cells (5 × 106cells) by electroporation (0.45 kV for 8-10 msec). After 48 h of transient expression, the cells were lysed in 500 µl of an ice-cold lysis buffer containing 20 mM Tris-HCl, pH 7.5, 120 mM NaCl, 1% (v/v) Triton X-100, 2 mM beta -mercaptoethanol, 5 mM benzamidine, 50 µg/ml leupeptin, 50 µg/ml aprotinin, 50 µg/ml trypsin inhibitor, 5 µg/ml pepstatin, 1 mM phenylmethylsulfonyl fluoride, 20 mM NaF, 1 mM Na3VO4, 1 mM p-nitrophenyl phosphate, and 5 mM imidazole. The suspension was stroked 20 times in a Dounce homogenizer and centrifuged at 12,000 × g for 30 min at 4 °C. Recombinant mutant or WT PKCalpha in the Triton-soluble extract was purified with nickel-agarose (Qiagen) using a batch procedure described before (13) and subsequently eluted in lysis buffer (0.02% Triton X-100) supplemented with 100 mM imidazole.

For treatment with phorbol esters, the culture medium was changed after 30 h of transient expression and 500 nM 12-O-tetradecanoylphorbol-13-acetate (TPA) was added. At various time points, the incubation medium was removed, and cells were quickly rinsed in ice-cold phosphate-buffered saline and lysed in lysis buffer (as above but without imidazole) supplemented with 10 µM microcystin. The lysate was passed twice through a 27-gauge needle and centrifuged for 20 min at 12,000 × g at 4 °C before analysis on SDS-PAGE.

For pulse-chase experiments, the culture medium was removed after 24 h of transient expression and replaced by DMEM supplemented with 10% (v/v) dialyzed fetal calf serum. After 1 h, cells were pulse-labeled for 15 min with 100 µCi/ml of [35S]methionine (Amersham, Life Science) in DMEM plus 5% (v/v) dialyzed fetal calf serum. Chase was then started in DMEM supplemented with 10% fetal calf serum and 5 mM methionine and stopped after various time points. Cells were finally lysed, and PKC was purified with nickel-agarose as described above.

Protein Phosphatase 1 Treatment of Purified PKC

The gamma  isoform of human protein phosphatase 1 (PP1cgamma ) (15) was obtained as a recombinant protein after introduction of the pCW PP1 plasmid into competent Escherichia coli DH5alpha . Expression and purification were carried out as described in Refs. 13 and 16. Purified recombinant PKCalpha (eluted from Ni-agarose in the absence of NaF, Na3VO4, and p-nitrophenyl phosphate) was treated at 22 °C for 30 min with purified recombinant PP1cgamma in the presence of 1 mM MnCl2. Reactions were stopped by adding 10 µM microcystin.

Protein Assays and Analysis

Protein kinase C activity was assayed as described earlier (13) using Histone III-S as a substrate. Protein concentration was determined by the bicinchoninic acid method (Pierce) using bovine serum albumin as the standard. High resolution SDS-PAGE was performed on samples diluted twice in 5 × Laemmli buffer (17) using 12-cm long running gels containing 7.5% acrylamide and 0.06% bisacrylamide. Gels were transferred onto nitocellulose and subjected to immunoblotting using a polyclonal antibody raised against the C terminus of PKCalpha (18). Reproductions of autoradiographs were obtained as computer-scanned images.


RESULTS AND DISCUSSION

Aberrant Phosphorylation of S657A and S657D PKCalpha Mutants

Previously, it has been shown that PKCalpha is phosphorylated at Ser-657 (11). Using V8 protease digestion, high pressure liquid chromatography purification, and mass spectrometry analysis, serine 657 was found to be phosphorylated also in recombinant 32P-labeled PKCalpha expressed in COS cells.2 In order to study the role of this phosphorylation, substitution mutants were made to prevent (S657A) or partially mimic (S657D) phosphorylation at this site. Both Ser-657 site PKCalpha mutants were expressed in COS cells, fully recovered in the detergent-soluble fraction after lysis, and could be purified on Ni-agarose (Fig. 1). Unlike the WT PKCalpha molecule that migrates as a single 80-kDa band, a doublet was reproducibly detected for both the 657 site mutants. It would therefore appear that mutagenizing the 657 position in PKCalpha perturbs the overall processing of the kinase as observed 48 h after transient expression in COS cells. This contrasts with the previously studied PKCalpha Thr-638 site mutants (13) that displayed complete processing under similar conditions (Fig. 1). This "processing" is due to phosphorylation as judged by the action of protein phosphatases on the various forms generated (see below and Refs. 13 and 19); for simplicity, the processing/mobility shifts observed here are referred to as phosphorylations in the text.


Fig. 1. Purification of histidine-tagged PKCalpha WT and mutant proteins. WT PKCalpha and proteins with C-terminal mutations at either Thr-638 or Ser-657 were transiently expressed in COS cells. After 48 h, cells were lysed in buffer containing 1% Triton X-100, and the soluble fraction was tumbled with nickel-agarose beads (see "Experimental Procedures"). Bound material was eluted with 100 mM imidazole and run on SDS-PAGE followed by Western blot analysis using a PKCalpha -specific antibody. In the Triton-soluble extracts from COS cells after 48 h of transient expression, the respective doublets of the Ser-657 site PKCalpha mutants were identified on all occasions (n >=  8). However, for the S657A mutant, due to its lower abundance, the bottom band was sometimes poorly detected after the purification step (see for example Fig. 5A). The bars indicate the 97- and 67-kDa markers.
[View Larger Version of this Image (61K GIF file)]


In order to analyze the rate of phosphorylation of the Ser-657 mutants directly, pulse-chase experiments using 35S-labeled methionine were carried out after 30 h of transient expression of either WT PKCalpha , S657A, or S657D in COS cells. As shown in Fig. 2A, phosphorylation at 657 clearly plays a rate-limiting role in the accumulation of a fully phosphorylated PKCalpha . Following a 15-min period in [35S]methionine-containing medium, the subsequent rate of accumulation of phosphorylated forms of PKCalpha is much reduced in the S657A mutant. Following 40 min of chase, the WT PKCalpha has shifted completely from the primary translation product, and the majority is in a slowly migrating doublet by 80 min. By contrast, the primary translation product of the S657A mutant is barely 50% converted to the first more slowly migrating form by 80 min of chase. There is, also, little further phosphorylaytion during this time period. Conversely, the S657D mutant is already 50% converted to the first slowly migrating form following the 15-min labeling period. Subsequently, however, the S657D mutant is slower than WT PKCalpha in accumulating as a more fully phosphorylated form.


Fig. 2. Altered processing rate in PKCalpha Ser-657 site mutants. Pulse-chase experiments using 35S-labeled methionine were carried out on COS cells transiently expressing WT PKCalpha or Ser-657 site mutants as described under "Experimental Procedures." Chase periods are for the times (in min) indicated above each lane. Cell lysis and protein purification were performed as for Fig. 1. Purified PKCalpha samples were run on SDS-PAGE and transferred onto nitrocellulose. Upper panel, autoradiography; bottom panel, immunoblot. The heavy bars indicate 97- and 67-kDa markers. The small bars indicate the four species of PKCalpha detected.
[View Larger Version of this Image (50K GIF file)]


These results imply that, in this context, there are two primary phases of phosphorylation going on for PKCalpha . In the first, phosphorylation of Ser-657 plays a rate-limiting role. In the second, some property of the Ser-657 phosphorylated protein is required that is not effectively mimicked by an aspartic acid substitution. The aspartic acid substitution is, however, sufficient for and indeed promotes the first phase of phosphorylation. It can be surmised that, in the S657D mutant (and the S657A mutant), either there is a low kinase activity in the partially phosphorylated forms that prevents the second phase of phosphorylation or that there is some sensitivity to protein phosphatases that slows down the accumulation of fully phosphorylated PKCalpha . The biochemical analysis of these mutants, as described below, demonstrates that the partially phosphorylated mutant forms of PKCalpha are, in fact, both sensitive to protein phosphatases and of low activity (summarized in Fig. 7). The pulse-chase data alongside the results detailed in subsequent sections provide evidence for three components to Ser-657 phosphorylation: (i) the phosphorylation of Ser-657 is rate-limiting for the first phase of PKCalpha phosphorylation; (ii) Ser-657 phosphorylation is required for efficient second phase phosphorylation of PKCalpha ; and (iii) phosphorylation of Ser-657 contributes to "locking" fully phosphorylated PKCalpha in a closed, phosphatase-resistant conformation.


Fig. 7. A model of PKCalpha phosphorylation. The occupation of particular phosphorylation sites is indicated by the residue numbers in the diagram; the absence of a number implies that it is not phosphorylated. The possibility of a fourth (or more) site is also noted. Activity is indicated by shading from white (inactive) to black (fully active). The intermediate states are based upon activity determinations at 25 °C as detailed under "Experimental Procedures." However, it should be noted that this perceived activity may be influenced by thermal stability. For the WT PKCalpha , the phosphorylation is proposed to proceed with the initial phosphorylation of the 497 and 657 sites as indicated. This produces an intermediate form that is predicted to have partial activity (intermediate gray fill) and to be sensitive to protein phosphatases (solid line/open arrowhead). In the second phase of phosphorylation, the 638 site becomes occupied (and possibly one other undefined site indicated by ?), and the protein takes on a closed conformation, is thermostable, becomes resistant to phosphatase action (dotted line/open arrowhead) and is fully active (dark fill). This model is based upon the properties of the mutant forms of PKCalpha ; a summary of these properties is indicated in the diagram. In particular, note the rapid (heavy arrow) and slow (dotted arrow) phosphorylation of the two mutants in phase 1. In addition, note the open conformation of the S657A mutant, its thermal instability, and phosphatase sensitivity (solid line/open arrowhead).
[View Larger Version of this Image (31K GIF file)]


The conclusions to be drawn from these analyses are entirely consistent with the steady-state pattern of S657D PKCalpha expression, which displays both fully phosphorylated and partially phosphorylated species (see Fig. 2B; i.e. processing can go to completion for this PKCalpha mutant, but it is incomplete in the steady state). By contrast, for the WT PKCalpha , although fast migrating forms can be detected by pulse labeling techniques (Fig. 2A), these forms are rapidly phosphorylated such that they do not contribute significantly to the steady-state level of WT PKCalpha . Thus, fast migrating forms are poorly detected by Western blotting for WT PKCalpha (Fig. 2B).

The S657D PKCalpha Mutant Displays Functional Heterogeneity

The slow rate of phase 2 phosphorylation of the S657D PKCalpha mutant indicated that the partially phosphorylated form may be functionally compromised. In order to assess the relative specific activity and protein phosphatase sensitivity of the S657D PKCalpha mutant, WT and S657D PKCalpha were purified from COS cells as above and treated in vitro with PP1cgamma . As shown in Fig. 3A, the faster migrating S657D PKCalpha species (78 kDa) was sensitive to PP1cgamma while the slower migrating (80 kDa) species was not; the 80-kDa species behaved exactly as WT PKCalpha (80 kDa). There was very little change in activity associated with the dephosphorylation of the 78-kDa S657D PKCalpha (Fig. 3A), implying that this species does not contribute significantly to the determined activity. This is consistent with calculation of the specific activity of the S657D mutant; accounting for only the 80-kDa species yielded a specific activity for S657D PKCalpha which was 103% of that of WT PKCalpha .


Fig. 3. Heterogeneity of the PKCalpha S657D mutant. A, sensitivity of PP1 in vitro. Purified PKCalpha samples (30 µl) were treated for 30 min with an equal volume of PP1cgamma (50 units ml-1) in the absence (30) or presence (30m) of 10 µM microcystin. PP1cgamma vehicle buffer was added to control samples (0), which were kept on ice. After 30 min, 10 µM microcystin (final concentration) was added to arrest dephosphorylation, and samples were run on SDS-PAGE followed by Western blotting (upper panel) or assayed for kinase activity (bottom panel). In the upper panel, the three bars indicate the forms of PKCalpha detected. B, in vivo TPA treatment. After 30 h of transient expression of the PKCalpha S657D mutant, COS cells were challenged with TPA as described under "Experimental Procedures." Cells were lysed and fractionated, and extracts were run on SDS-PAGE and Western blotted. The Triton-soluble and -insoluble fractions are shown. In these panels, the three bars identify the species of PKCalpha observed. The dotted bars note the lower abundance of these species. This is one of two similar experiments.
[View Larger Version of this Image (39K GIF file)]


This data indicates that the fast migrating species is a low activity form that is sensitive to dephosphorylation. Previous studies on the PKCalpha Thr-638 site have correlated phosphatase hypersensitivity in vitro and in vivo (13). A similar correlation was found for the S657D PKCalpha mutant. Thus, on transient expression of S657D PKCalpha in COS cells, TPA treatment induced a rapid (<= 15 min) dephosphorylation of the fast migrating form but not the slow migrating form (Fig. 3B). As observed in vitro (Fig. 3A), the slow migrating form behaved essentially as WT PKCalpha (not shown) while the fast migrating form was hypersensitive to phosphatases. Notably, the S657D PKCalpha doublet was entirely Triton X-100-soluble in transfected cells, and only following TPA treatment did antigen accumulate in the Triton X-100-insoluble fraction.

In PKCalpha Thr-638 site mutants, phosphatase sensitivity parallels thermal instability (13). This appears to be due to an alteration in the way the C terminus (V5 domain) interacts with the catalytic core (C3/4 domain), producing an "open" conformation. For the S657D mutant, kinase activity is largely accounted for by a slowly migrating form that is phosphatase-resistant, i.e. behaves like WT PKCalpha . It can be predicted that this mutant would resemble the WT protein with respect to thermal inactivation, and this is, in fact, the case. Incubation at 25 °C for 30 min induced a 5% loss of activity precisely that observed for WT PKCalpha (Fig. 4). By way of comparison under these same conditions, the Thr-638 mutants (that do not accumulate as partially phosphorylated forms, see Fig. 1) displayed a much greater degree of thermal inactivation. The S657A mutant displayed an intermediate loss of activity (see below).


Fig. 4. Thermal stability of the PKCalpha C-terminal phosphorylation mutants. Purified WT PKCalpha and C-terminal mutants were assayed for their residual kinase activity following a 30-min incubation at 25 °C in the presence of 10 µM microcystin. Untreated samples were kept on ice for reference. Activity values shown are the mean of duplicates and are representative of two separate determinations.
[View Larger Version of this Image (71K GIF file)]


The properties of the two differentially phosphorylated S657D species indicate that once fully phosphorylated, the aspartic acid substitution is sufficient to mimic any requirement for phosphorylation at this site. This is reflected in the full activity, phosphatase resistance (in vitro and in vivo), and thermal stability of the kinase activity. However, it is equally evident that the partially phosphorylated (fast migrating) form is of low activity and is phosphatase-sensitive. It is these latter properties that would account for the slow second phase of S657D PKCalpha phosphorylation as discussed above.

S657A PKCalpha Reveals a Stabilizing Role for the 657 Phosphorylation Site

Contrary to the S657D substitution, S657A PKCalpha could be dephosphorylated and inactivated in vitro by PP1cgamma (Fig. 5A). However, the extent of inactivation correlated with the dephosphorylation of the slower migrating form, indicating that, as for S657D PKCalpha , the faster migrating form contributes little to the overall perceived activity. Accounting for only the upper slow migrating S657A PKCalpha species reveals a specific activity for this protein of 109% of the WT PKCalpha . The results demonstrate that phosphorylation of this site is not essential for catalysis but affects phosphatase sensitivity in vitro.


Fig. 5. Lack of phosphate on Ser-657 correlates with increased phosphatase sensitivity. A, sensitivity of PKCalpha S657A to PP1cgamma in vitro. Purified PKCalpha S657A was treated with PP1cgamma for 30 min in the absence (30) or presence (30m) of 10 µM microcystin as described in the legend to Fig. 3. The upper panel shows a Western blot of the control and treated samples. The lower panel indicates the change in activity. B, in vivo TPA treatment of PKCalpha S657A. The mutant was expressed, extracted, and fractionated for Western analysis as described in the legend to Fig. 3. The bars indicate the species of PKCalpha observed; the dotted bar notes the lower abundance of this species. This is one of two similar experiments.
[View Larger Version of this Image (25K GIF file)]


Phosphatase hypersensitivity of S657A PKCalpha was observed also in vivo (Fig. 5B). Thus, on TPA treatment of S657A PKCalpha transfected COS cells, the mutant was dephosphorylated with virtually complete loss of the most highly phosphorylated form by 15 min. As described for the S657D mutant, the dephosphorylated form accumulated in the Triton X-100-insoluble fraction; prior to TPA treatment, the S657A PKCalpha forms were fully Triton X-100 extractable (discussed below).

The observed increased sensitivity to phosphatases for S657A PKCalpha , redistribution to the cytoskeleton, and the loss of activity observed on dephosphorylation in vitro suggests that phosphorylation at the 657 site (or an aspartic acid) normally contributes to the "closed" conformation (V5-C3/4 interacting; see Ref. 13) of the protein. Consistent with this view was the moderate thermal instability of the S657A PKCalpha kinase activity noted above (see Fig. 4). Thus, it would seem that phosphorylation of the 657 site not only influences the accumulation of phosphate as described above but also contributes to maintaining the active closed conformation (i.e. effective V5-C3/4 interactions). Evidence that this is the case is suggested by studies with PKCalpha mutants altered at the Thr-497 or Thr-497 and Thr-638 sites. The T497E/T638E mutant retains reduced protein kinase activity, but this mutant can still be inactivated by PP1cgamma similar to the T497E mutant (Fig. 6). While not necessarily the only other regulatory phosphorylation site on PKCalpha , the phosphatase-dependent inactivation of the T497E/T638E mutant is consistent with Ser-657 dephosphorylation. This conclusion is further supported by the finding that an T497E/T638E/S657E mutant is both inactive and, by migration, insensitive to TPA-induced dephosphorylation in vivo (data not shown).


Fig. 6. Phosphates on Ser-657 and Thr-638 cooperate to maintain kinase activity. Purified His-tagged PKCalpha T497E and T497E/T638E mutants were treated with PP1cgamma for the times indicated in the absence (open circles) or presence (filled circles) of 10 µM microcystin. Dephosphorylation was quenched by adding 10 µM microcystin, and kinase activity was immediately assayed (upper panel). Values shown are the mean of duplicates. The same samples were run in SDS-PAGE and Western blotted (lower panel). 0, 30, 60, and 120 relate to the time course in minutes; 120m indicates the presence of microcystin during the incubation. The arrowheads denote the slowest and fastest migrating species of the PKCalpha mutants observed. For both mutants, the pattern of dephosphorylation obtained is representative of two different experiments.
[View Larger Version of this Image (30K GIF file)]


A Model for the Phosphorylation Control of PKCalpha

The properties and phosphorylation of the S657A and S657D PKCalpha mutants are summarized in Fig. 7, alongside those predicted for the WT PKCalpha . The presence of phosphate in the Thr-497 site in the low/partial activity form resulting from "phase 1" is based upon mapping of 32P-labeled peptides from the fast migrating form of the S657D mutant (data not shown). The phosphorylation of Thr-638 in the second phase is predicted from the dominant role this site has in controlling the rate of dephosphorylation of PKCalpha (13). For the most highly phosphorylated forms, the effects of the Ser-657 site are defined by the S657A mutant, which demonstrates no absolute requirement for phosphorylation to yield full activity but a requirement for phosphorylation (or an acidic residue) to enhance thermal stability and maintain a phosphatase-resistant state. The basis of these properties likely relates to the closed conformation consequent to the V5-C3/4 domain interactions (13). Thus, the Ser-657 phosphorylation appears to play a role alongside that of Thr-638 in forming this closed conformation although the Thr-638 site is dominant in this regard. This dominance of the Thr-638 site is evidenced by the greater phosphatase sensitivity (13) and thermal instability of the T638A compared with the S657A mutant.

The partially phosphorylated forms of both the S657A and S657D mutants are of low activity, and this is consistent with the slow progress of phase 2 compared with WT PKCalpha . It can be concluded then that the conformation/activity of the partially phosphorylated WT PKCalpha is more favorable for completion of phase 2. The attainment of this partially phosphorylated state is also dependent upon Ser-657 phosphorylation, as evidenced by the pulse-chase experiments with the 657 site mutants. These reveal a rate-limiting role for Ser-657 phosphorylation in phase 1. While this phase appears to lead to phosphorylation of the Ser-657 and Thr-497 sites in WT PKCalpha , the fact that Ser-657 phosphorylation is rate-limiting does not define the order of these events.

A unifying hypothesis derived from these studies and those on Thr-638 site mutants (13) is that the phosphorylated Ser-657 site contributes to contact between the C-terminal (V5) domain and the catalytic core (C3/4). In the partially phosphorylated state (no Thr-638 phosphorylation), phosphate at Ser-657 acts alone to generate the appropriate conformation, and aspartic acid substitution is an insufficient surrogate. In the fully phosphorylated state, this conformation is contributed by both the Thr-638 and Ser-657 sites; here, aspartic acid substitution is sufficient to act in synergy with phosphate at the Thr-638 site. Contrary to previous conclusions (11, 20), these priming phosphorylations are not involved in solubilizing the primary translation product as evidenced by the complete solubility of the mutants described here. In fact, the detergent-insoluble form that can accumulate in cells is associated with dephosphorylation of the activated enzyme. This property of the dephosphorylated enzyme distinguishes it from the primary translation product that is soluble, indicative of either a selective mechanism for sequestration of the membrane-associated dephosphorylated form or the existence of a chaperone protein operating on the primary translation product to maintain solubility and permit appropriate folding/phosphorylation. In view of the poor solubility of PKCalpha expressed even at low levels in E. coli,3 the existence of a mammalian chaperone would seem a probable mechanism. This conclusion is further supported by the finding that dephosphorylation of WT PKCalpha in vitro leads to aggregation and insolubility of the protein.3

The results presented here and previously (13) on PKCalpha define the processes involved in generating and maintaining an active kinase. The implications of these findings are broad. There are a number of protein kinases that, like PKCalpha , have conserved threonine and serine sites in locations equivalent to Thr-638 and Ser-657. For example, of particular current interest is the control of the PKB/akt/RAC kinase. This protein has recently been shown to be fully activated in an agonist-dependent fashion through phosphorylation in both its catalytic core (activation loop) site (residue T308) and in a C-terminal site equivalent to Ser-657 in PKCalpha (PKB residue S473) (21). The manner of operation of these sites in PKB is likely to be as that described here for PKCalpha .

In respect of the Ser-657 site itself, this site lies within an FSF/Y motif. In p70S6kinase, the phosphorylation of the equivalent site within the same motif is sensitive to rapamycin (22); no such sensitivity is observed for PKCalpha ,3 implying a distinct mechanism of control. Interestingly, in PKCzeta and in the PRK family, this equivalent site is substituted by an acidic residue (23-25). Based upon the mutants described here, this would not affect the fully phosphorylated form, but it may presage the existence of low activity forms of these proteins that are subject to control by acute phosphorylation and activation. Evidence that this may be the case exists for PRK1(PKN) (26). The implications of the pattern and consequence of PKCalpha phosphorylation thus impact on a number of related kinases, and it will be of great interest to see how well conserved these properties indeed are and how they integrate into the distinct modes of regulation of these kinases.


FOOTNOTES

*   This work was supported in part by a European Community fellowship (to F. B.) and Biomed Program Support (to P. J. P.). The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    Current address: Synthelabo Recherche (L.E.R.S.), 31 Avenue Paul Vaillant-Couturier, 92220 Bagneux, France.
§   To whom correspondence should be addressed: The Imperial Cancer Research Fund, P. O. Box 123, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom.
1    The abbreviations used are: PKC, protein kinase C; DMEM, Dulbecco's modified Eagle's medium; TPA, 12-O-tetradecanoylphorbol-13-acetate; PAGE, polyacrylamide gel electrophoresis; PP1cgamma , gamma  isoform of human protein phosphatase 1; WT, wild-type.
2    F. Bornancin, D. Rahman, D. J. C. Pappin, and P. J. Parker, unpublished data.
3    F. Bornancin, and P. J. Parker, unpublished data.

Acknowledgments

We thank Dr. P. T. W. Cohen and coworkers for providing us with the pCW-PP1 plasmid and Louise Mansi for preparation of the manuscript. We are grateful to Drs. L. Dekker and M. Parker for constructive comments on the manuscript. We are indebted to Dr. B. Hemmings for providing data prior to publication.


REFERENCES

  1. Heilmeyer, L. (1991) Biochim. Biophys. Acta 1094, 168-174 [Medline] [Order article via Infotrieve]
  2. Cobb, M. H., and Goldsmith, E. J. (1995) J. Biol. Chem. 270, 14843-14846 [Free Full Text]
  3. Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995) Nature 378, 785-789 [CrossRef][Medline] [Order article via Infotrieve]
  4. Johnson, L. N., Noble, M. E., and Owen, D. J. (1996) Cell 85, 149-158 [Medline] [Order article via Infotrieve]
  5. Taylor, S. S., Buechler, J. A., and Yonemoto, W. (1990) Annu. Rev. Biochem. 59, 971-1005 [CrossRef][Medline] [Order article via Infotrieve]
  6. Knighton, D. R., Zheng, J., Ten-Eyck, L. F., Xuong, N.-H., Taylor, S. S., and Sowadski, J. M. (1991) Science 253, 414-420 [Medline] [Order article via Infotrieve]
  7. Knighton, D., Zheng, J., Ten-Eyck, L., Ashford, V., Xuong, N., Taylor, S., and Sowadski, J. (1991) Science 253, 407-414 [Medline] [Order article via Infotrieve]
  8. Cazaubon, S., Bornancin, F., and Parker, P. J. (1994) Biochem. J. 301, 443-448 [Medline] [Order article via Infotrieve]
  9. Cazaubon, S. M., and Parker, P. J. (1993) J. Biol. Chem. 268, 17559-17563 [Abstract/Free Full Text]
  10. Orr, J. W., and Newton, A. C. (1994) J. Biol. Chem. 269, 27715-27718 [Abstract/Free Full Text]
  11. Keranen, L. M., Dutil, E. M., and Newton, A. C. (1995) Curr. Biol. 5, 1394-1403 [Medline] [Order article via Infotrieve]
  12. Tsutakawa, S. E., Medzihradszky, K. F., Flint, A. J., Burlingame, A. L., and Koshland, D. E., Jr. (1995) J. Biol. Chem. 270, 26807-26812 [Abstract/Free Full Text]
  13. Bornancin, F. P., and Parker, P. J. (1996) Curr. Biol. 6, 1114-1123 [Medline] [Order article via Infotrieve]
  14. Parker, P. J., Coussens, L., Totty, N., Rhee, L., Young, S., Chen, E., Stabel, S., Waterfield, M. D., and Ullrich, A. (1986) Science 233, 853-859 [Medline] [Order article via Infotrieve]
  15. Barker, H. M., Brewis, N. D., Street, A. L., Spurr, N. K., and Cohen, P. T. W. (1994) Biochim. Biophys. Acta 1220, 212-218 [CrossRef][Medline] [Order article via Infotrieve]
  16. Alessi, D. R., Street, A. J., Cohen, P., and Cohen, P. T. W. (1993) Eur. J. Biochem. 213, 1055-1066 [Abstract]
  17. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  18. Marais, R. M., and Parker, P. J. (1989) Eur. J. Biochem. 182, 129-137 [Abstract]
  19. Pears, C., Stabel, S., Cazaubon, S., and Parker, P. J. (1992) Biochem. J. 283, 515-518 [Medline] [Order article via Infotrieve]
  20. Newton, A. C. (1995) J. Biol. Chem. 270, 28495-28498 [Free Full Text]
  21. Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., and Hemmings, B. A. H. (1996) EMBO J., in press
  22. Pearson, R. B., Dennis, P. B., Han, J. W., Williamson, N. A., Kozma, S. C., Wettenhall, R. E. H., and Thomas, G. (1995) EMBO J. 14, 5279-5287 [Abstract]
  23. Ono, Y., Fujii, T., Ogita, K., Kikkawa, U., Igarashi, K., and Nishizuka, Y. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 3099-3103 [Abstract]
  24. Mukai, H., and Ono, Y. (1994) Biochem. Biophys. Res. Commun. 199, 897-904 [CrossRef][Medline] [Order article via Infotrieve]
  25. Palmer, R. H., Ridden, J., and Parker, P. J. (1995) Eur. J. Biochem. 227, 344-351 [Abstract]
  26. Amano, M., Mukai, H., Ono, Y., Chihara, K., Matsui, T., Hamajima, Y., Okawa, K., Iwamatsu, A., and Kaibuchi, K. (1996) Science 271, 648-650 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.